No Patients to Resect or Transplant: An Analysis of Patients with Hepatocellular Carcinoma Admitted to a Major African Referral Hospital

Abstract

The majority of HCC in our population is caused by HBV. Up to 61 % of patients may be eligible for curative treatment, transarterial chemoembolization, or sorafenib treatment. This percentage may be increased with a robust surveillance program for patients at increased risk for HCC. Hepatitis B vaccination must also be a public health priority.